文摘
肺表面活性剂蛋白质a (SP-A)是一个主要phospholipid-associated糖蛋白在表面活性剂,并为肺腺癌是一种有用的免疫组织化学标记。癌胚抗原(CEA)尚未在间皮瘤免疫组织化学检测。在胸膜腔积液由于恶性间皮瘤,SP-A浓度很低,东航可以预期。我们研究的价值总和决定CEA和SP-A胸膜液体区分肺腺癌和间皮瘤。SP-A和CEA浓度测定在胸膜腔积液78例肺腺癌与恶性间皮瘤和10。SP-A浓度在胸膜腔积液因肺腺癌和间皮瘤是516 + / - 140和16.9 + / - 3.6 ng。ml-1(意思是+ / - SEM),分别。在胸腔积液CEA浓度由于肺腺癌和间皮瘤是239 + / - 92.4和1.7 + / - 0.3 ng。分别ml-1。SP-A值没有超过100 ng。ml-1的10间皮瘤能够,而78年37肺腺癌。CEA值不超过10 ng。ml-1 in any of 10 mesotheliomas, whilst in 53 of 78 lung adenocarcinomas they did. Increased values of SP-A and/or CEA were found in pleural effusions from 67 of 78 lung adenocarcinomas. It is concluded that a combination of CEA and SP-A assays in pleural effusions will be helpful for discriminating lung adenocarcinoma from mesothelioma.